adivo
Key Facts
| Invested since | 2018 |
| Based in | Bavaria |
About the company
adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.
Do you want to
know more about this company?
adivo in the news
Zum Artikel
Successful exit for HTGF: adivo joins Zoetis to bring the benefits of species-specific antibody therapies to pet owners worldwide
More startups from Life Sciences
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
To the complete profileof Lindis Blood Care
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the …
To the complete profileof TolerogenixX
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is …
To the complete profileof Draupnir Bio
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain …
To the complete profileof Sedivention
Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA …
To the complete profileof Pantherna Therapeutics
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Our G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only …
To the complete profileof Akribion Therapeutics
The company was founded in 2022 and is headquartered at the STIMULATE research campus in Magdeburg’s “science-harbour”. The scientific company is a spin-off by scientists from the Otto-von-Guericke-University Magdeburg. The …
To the complete profileof RAYDIAX
Heidelberg Epignostix is a healthcare company whose mission is to transform cancer diagnostics through data science. The company has developed novel AI-based bioinformatics algorithms with utility in cancer classification for …
To the complete profileof Heidelberg Epignostix
Preventicus GmbH is developing smartphone-driven solutions to capture and analyze patients’ vital parameters for early preclinical risk screening of lifestyle-related illnesses. Seed funding for the Jena-based company is managed by …
To the complete profileof Preventicus
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying. The …
To the complete profileof trans.duodenal.concepts
Exit
Amedrix develops & produces three dimensional implants (gel and liquid) based on collagen. Focus: treatment of articular cartilage damage in human an horse and other promising application areas. CE-mark for …
To the complete profileof Amedrix
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a …
To the complete profileof Tubulis